Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

784 - Induction chemotherapy followed by concurrent chemoradiation (CCRT) in unresectable locally advanced head and neck cancer (LAHNC)


20 Dec 2015


Poster presentation 2


Sitthinon Rungjarassiri


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


S.-. Rungjarassiri1, S. Wongsrita1, I. Chitapanarux1, P. Klunklin1, P. Traisathit2

Author affiliations

  • 1 Therapeutic Radiology And Oncology, Maharaj Nakorn Chiang Mai Hospital Faculty of Medicine, 50200 - Chiang Mai/TH
  • 2 Division Of Statistics, Faculty Of Science, Chiang Mai university, 50200 - Chiang Mai/TH


Abstract 784


Induction treatment with Docetaxel/Cisplatin/5-FU (TPF) in TAX 324 study was evaluated from 3 mixed groups of patients (technical unresectibility, low surgical curability and organ preservation). Conversely, most of LAHNC patients in our center are unresectibility. This study was intended to evaluate the outcomes of induction TPF followed by CCRT in unresectable LAHNC.


Between January 2009 and December 2013, we retrospectively analyzed the outcomes in 30 unresectable LAHNC patients who received induction TPF (Docetaxel 75 mg/m2 on day 1, Cisplatin 75 mg/m2 on day 1, 5-fluorouracil 750 mg/m2 on day 1-4, every 3 weeks), followed by CCRT with weekly Carboplatin (AUC 2) at Maharaj Nakorn Chiang Mai Hospital.


Most of the patients were male (97%) with a median age of 52.1 years (range 47.8–55.9). All patients had good performance status (ECOG 0-1). Site of cancer consisted of oropharynx 53%, hypopharynx 37%, larynx 7% and oral cavity 3%. Squamous cell carcinoma was found in 97%. Seventy – four percent of patients completely received 3 cycles of induction TPF and 81% completely received at least 5 cycles of concurrent carboplatin. With the median follow-up of 12.4 months, the median survival was 12 months. No patients in our study received salvage surgery even having residual disease or N2/N3 at diagnosis. The 2-year overall survival and disease-free survival were 40% and 59%, respectively. We found grade 3-4 neutropenia in 20% of patients, and grade 3 thrombocytopenia in 3% of patients.


Our induction TPF followed by CCRT outcomes were inferior to TAX 324 study. We believe that salvage surgery may have the role in this group of patients.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings